Tulsi Bhandari

Tulsi Bhandari

Auto-generated profile, based on publicly available information

Tulsi Bhandari

Rieveschl Laboratories for Mass Spectrometry, University of Cincinnati Department of Chemistry Cincinnati , OH 45221

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 September 2025 in Nucleic Acids Research
Verified
Journal Article
Open access
MHMartin Hengesbach
Martin Hengesbach
CCChi-Kong Chan
Chi-Kong Chan
TBTulsi Bhandari
Tulsi Bhandari
ABAlan Bruzel
Alan Bruzel
MDMichael S DeMott
Michael S DeMott
PLPatrick Limbach
Patrick Limbach
The human RNome comprises all forms of RNA and the 50 + chemical structures—the epitranscriptome—that modify them. Understanding the diverse functions of RNA modifications in regulating gene expression and cell phenotype requires technologies such as RNA sequencing-based modification mapping and mass spectrometry-based quantification of modified ribonucleosides. Liquid chromatography-coupled tandem quadrupole mass spectrometry (LC–MS/MS) is the gold standard for detecting and quantifying modified ribonucleosides with accuracy and precision. However, variations in RNA isolation, processing, and LC–MS/MS analysis have hindered reproducibility across laboratories, which is essential for accurate quantification of RNA modifications. As guidance toward harmonization, we report a multi-laboratory comparison of workflows for LC–MS/MS RNA modification analysis. We compared protocols for sample shipment, RNA hydrolysis, LC–MS/MS analysis, and data processing among three laboratories working with the same total RNA samples. We detected and quantified 17 modifications consistently across protocols and operators, with another 7 that were sensitive to experimental conditions, reagent contamination, and ribonucleoside instability, leading to poor precision among laboratories. Agreement among the three labs was strong, with coefficients of variation of 20% and 10% for relative and absolute quantification, respectively. These findings establish a robust and readily adoptable epitranscriptome analytical platform that enables reliable comparisons across laboratories.

7 November 2024 in Molecular Neurobiology
Verified
Journal Article
Open access
PDF file
Gowthami MahendranGowthami Mahendran
Gowthami Mahendran
KBKurtis Breger
Kurtis Breger
PMPhillip McCown
Phillip McCown
JHJacob P. Hulewicz
Jacob P. Hulewicz
TBTulsi Bhandari
Tulsi Bhandari
JBJessica Brown
Jessica Brown
Miller-Dieker syndrome (MDS) is a rare neurogenetic disorder resulting from a heterozygous deletion of 26 genes in the MDS locus on human chromosome 17. MDS patients often die in utero and only 10% of those who are born reach 10 years of age. Current treatments mostly prevent complications and control seizures. A detailed understanding of the pathogenesis of MDS through gene expression studies would be useful in developing precise medical approaches toward MDS. To better understand MDS at the molecular level, we performed RNA sequencing on RNA and mass spectrometry on total protein isolated from BJ (non-MDS) cells and GM06097 (MDS) cells, which were derived from a healthy individual and an MDS patient, respectively. Differentially expressed genes (DEGs) at the RNA and protein levels involved genes associated with phenotypic features reported in MDS patients (CACNG4, ADD2, SPTAN1, SHANK2), signaling pathways (GABBR2, CAMK2B, TRAM-1), and nervous system development (CAMK2B, BEX1, ARSA). Functional assays validated enhanced calcium signaling, downregulated protein translation, and cell migration defects in MDS. Interestingly, overexpression of methyltransferase-like protein 16 (METTL16), a protein encoded in the MDS locus, restored defects in protein translation, phosphor states of mTOR (mammalian target of rapamycin) pathway regulators, and cell migration in MDS cells. Although DNA- and RNA-modifying enzymes were among the DEGs and the intracellular SAM/SAH ratio was eightfold lower in MDS cells, global nucleoside modifications remained unchanged. Thus, this study identified specific genes and pathways responsible for the gene expression changes, which could lead to better therapeutics for MDS patients.